Теклистамаб

Rec. INN (наименование, зарегистрированное ВОЗ)

DB16655

Противоопухолевые средства — моноклональные антитела

N (не классифицировано FDA)

2119595-80-9

immunoglobulin G4-lambda, anti-[Homo sapiens TNFRSF17 (TNF receptor superfamily member 17, tumor necrosis factor receptor superfamily, member 17, B cell maturation antigen, BCMA, BCM, TNFRSF13A, CD269)] and anti-[Homo sapiens CD3 epsilon (CD3E, Leu-4)], monoclonal antibody, bispecific; gamma4 heavy chain anti-TNFRSF17 (1-448) [VH (Homo sapiens IGHV4-39*01 (97.0%) -(IGHD) -IGHJ4*01 (100%)) [10.7.13] (1-121) -Homo sapiens IGHG4*01, nG4m(a) CH2 L92, G4v5 h P10, G4v4 CH2 A1.3, A1.2 (CH1 (122-219), hinge S10>P (229) (220-231), CH2 L92 (310), F1.3>A (235), L1.2>A (236) (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135- 213')-disulfide with lambda light chain anti-TNFRSF17 (1'-214') [V-LAMBDA (Homo sapiens IGLV3-21*02 (96.9%) -IGLJ2*01 (100.0%)) [6.3.11] (1'-108') -Homo sapiens IGLC2*01 (99.1%) A43>G (152) (109'-214')];
gamma4 heavy chain anti-CD3E (1''-452'') [VH (Mus musculus IGHV10-1*02 (89.8%) -(IGHD) -IGHJ3*01 (93.3%)/Homo sapiens IGHV3-72*01 (88.0%) -(IGHD) -IGHJ6*01 (90.9%)) [8.10.16] (1''- 125'') -Homo sapiens IGHG4*01, nG4m(a) CH2 L92, G4v5 h P10, G4v4 CH2 A1.3, A1.2, G4v10 CH3 F85.1, K88 (CH1 (126- 223), hinge S10>P (233) (224-235), CH2 L92 (314), F1.3>A (239), L1.2>A (240) (236-345), CH3 F85.1>L (410), R88>K (414) (346-450), CHS (451-452)) (126''-452'')], (139''-214''')-disulfide with lambda light chain anti-CD3 (1'''-215''') [V-LAMBDA (Homo sapiens IGLV7-43*01 (81.9%) -IGLJ3*02 (100%)) [9.3.9] (1'''- 109''') -Homo sapiens IGLC2*01 (100%) (110'''-215''')]; dimer (231-227':234''-230''')-bisdisulfide

C₆₃₈₃H₉₈₄₇N₁₆₉₅O₂₀₀₃S₄₀

143662,25 г/моль

Поделиться этой страницей